サンプル依頼リスト カート
  • English
  • Korean
表紙：月経周期異常の世界市場レポート 2024年
市場調査レポート
商品コード
1415676

月経周期異常の世界市場レポート 2024年

Cyclic Heavy Menstrual Bleeding Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
月経周期異常の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

月経周期異常市場規模は近年力強く成長しています。2023年の402億1,000万米ドルから2024年には429億7,000万米ドルに、CAGR6.9％で拡大します。実績期間の成長は、人口の高齢化、月経の健康に対する意識の向上、可処分所得の増加、政府の取り組みに起因しています。

月経周期異常市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR6.0％で542億7,000万米ドルに成長します。予測期間の成長は、女性人口の増加、肥満の有病率の上昇、ヘルスケアへのアクセスの増加、バイオシミラーの人気の高まり、予防治療への需要の高まりに起因すると考えられます。予測期間における主な動向には、医療の進歩、低侵襲手術、栄養学的アプローチ、環境に優しい生理用品などがあります。

子宮筋腫およびポリープの罹患率の上昇は、当面の月経周期異常市場拡大のカタリストとして機能すると予測されます。子宮筋腫および子宮ポリープは、女性の子宮内に発生する可能性のある一般的な非がん性増殖です。これらの疾患の治療は、出血量の減少、月経周期の調整、合併症の予防、月経障害と闘う個人の精神的な幸福の向上において極めて重要な役割を果たしています。例えば、2022年3月現在、スイスの学術誌『Frontiers』に掲載されたデータでは、米国で無作為に選ばれた35歳から49歳の女性1,346人を対象に実施された調査の結果が報告されています。自己申告に頼ったこの調査では、アフリカ系アメリカ人女性の35歳までの子宮筋腫発症率は60％で、50歳までに80％以上に増加することが明らかになった。対照的に、同じ調査の白人女性では、35歳までの子宮筋腫発生率は40％で、50歳までに70％近くまで上昇しました。したがって、子宮筋腫とポリープの有病率の増加は、月経周期異常市場の成長の原動力となっています。

月経衛生に関する意識の高まりと政府のイニシアチブの実施は、当面の月経周期異常市場成長の原動力として機能する見込みです。月経に関する健康意識には、月経周期、生殖に関する健康、月経を経験する個人の身体的・精神的な幸福に関連する様々な側面に関する知識、理解、認識が含まれます。社会的タブーに対処し、月経にまつわる神話や誤解を払拭し、個人が自信を持って尊厳をもって月経の健康を管理し、必要な資源を利用できるようにすることを目的としています。例えば、2022年5月現在、米国の金融機関である世界銀行は、ガーナ政府が「GAMA衛生・水プロジェクト」を導入したと報告しています。この取り組みには、学校における月経衛生管理（MHM）介入が思春期の女児の教育活動に及ぼす影響を探る包括的な定性的調査が含まれていました。このプロジェクトでは、グレーター・アクラ首都圏の260以上の学校に衛生施設を建設しました。これらの施設には、女児用の独立した安全なトイレと更衣室があり、ドアには鍵がかけられ、衛生的で安全な使用済み生理用品の廃棄場所と手洗い設備が備わっていました。その結果、月経に関する健康意識の高まりと政府の取り組みが、月経周期異常市場の成長を促す要因となっています。

2023年の月経周期異常市場では北米が最大地域でした。月経周期異常レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の月経周期異常市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 頻発月経
  • 希発月経
  • 子宮出血
  • 世界の月経周期異常市場、治療タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 薬剤
  • ホルモン療法
  • 手術
  • 世界の月経周期異常市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • 世界の月経周期異常市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院
  • 在宅ケア
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の月経周期異常市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の月経周期異常市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 周期的大量月経出血市場の競合情勢
  • 周期性大量月経出血市場の企業プロファイル
    • Pfizer Inc.
    • Merck and Co. Inc.
    • Novartis AG
    • Abbott Laboratories
    • GlaxoSmithKline Plc

第31章 その他の主要および革新的な企業

  • Medtronic Plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Reckitt Benckiser Group Plc
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Bausch Health Companies Inc.
  • Eisai Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Perrigo Company PLC
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Cipla Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12275

“Cyclic Heavy Menstrual Bleeding Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cyclic heavy menstrual bleeding market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cyclic heavy menstrual bleeding? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The cyclic heavy menstrual bleeding market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Polymenorrhea; Oligomenorrhea; Metrorrhagia
  • 2) By Treatment Type: Medication; Hormonal Therapy; Surgery
  • 3) By Route of Administration: Oral; Parenteral
  • 4) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Merck and Co. Inc.; Novartis AG; Abbott Laboratories; GlaxoSmithKline Plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Cyclic heavy menstrual bleeding is a medical condition characterized by abnormally heavy and prolonged menstrual periods that occur regularly on a monthly cycle. It can result from a variety of factors, including hormonal imbalances, uterine fibroids, polyps, adenomyosis (a condition in which the uterine lining grows into the muscular wall of the uterus), certain medications, or underlying medical conditions. The treatment for this condition involves employing a range of medical strategies and interventions to effectively manage its symptoms and associated complications.

The primary types of cyclic heavy menstrual bleeding include polymenorrhea, oligomenorrhea, and metrorrhagia. Polymenorrhea is a medical term used to describe menstrual cycle irregularities where a woman experiences menstrual periods more frequently than the typical cycle length of approximately 21 to 35 days. Treatment options encompass medications, hormonal therapy, and surgical procedures, with various methods of administration such as oral and parenteral. These treatments are utilized by diverse end-users, including hospitals, home-based care, specialty clinics, and others.

The cyclic heavy menstrual bleeding market research report is one of a series of new reports from The Business Research Company that provides cyclic heavy menstrual bleeding market statistics, including cyclic heavy menstrual bleeding industry global market size, regional shares, competitors with a cyclic heavy menstrual bleeding market share, detailed cyclic heavy menstrual bleeding market segments, market trends and opportunities and any further data you may need to thrive in the cyclic heavy menstrual bleeding industry. This cyclic heavy menstrual bleeding market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cyclic heavy menstrual bleeding market size has grown strongly in recent years. It will grow from $40.21 billion in 2023 to $42.97 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to aging population, raise awareness about menstrual health, rising disposable incomes, government initiatives.

The cyclic heavy menstrual bleeding market size is expected to see strong growth in the next few years. It will grow to $54.27 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing female population, rising prevalence of obesity, increasing access to healthcare, growing popularity of biosimilars, increasing demand for preventive treatments. Major trends in the forecast period include medical advancements, minimally invasive procedures, nutritional approaches, eco-friendly menstrual products.

The escalating incidence of uterine fibroids and polyps is anticipated to serve as a catalyst for the expansion of the cyclic heavy menstrual bleeding market in the foreseeable future. Uterine fibroids and uterine polyps are common noncancerous growths that can develop within the uterus (womb) of women. Treatment for these conditions plays a pivotal role in reducing blood loss, regulating the menstrual cycle, preventing complications, and improving the emotional well-being of individuals grappling with menstrual disorders. For instance, as of March 2022, data published in Frontiers, a journal based in Switzerland, reported the results of a survey conducted in the United States among 1,346 randomly selected women aged 35 to 49. The survey, which relied on self-reporting, revealed a 60% incidence of uterine fibroids by age 35 among African-American women, which increased to over 80% by age 50. In contrast, Caucasian women in the same study exhibited an incidence of 40% by age 35, escalating to nearly 70% by age 50. Hence, the increasing prevalence of uterine fibroids and polyps is a driving force behind the growth of the cyclic heavy menstrual bleeding market.

The increasing awareness regarding menstrual health and the implementation of government initiatives are poised to act as driving forces for the growth of the cyclic heavy menstrual bleeding market in the foreseeable future. Menstrual health awareness encompasses the knowledge, understanding, and acknowledgment of various aspects related to the menstrual cycle, reproductive health, and the physical and emotional well-being of individuals experiencing menstruation. It aims to address social taboos, dispel myths and misconceptions surrounding menstruation, and empower individuals to manage their menstrual health confidently, with dignity, and access to essential resources. For instance, as of May 2022, the World Bank, a US-based financial institution, reported that the government of Ghana introduced The GAMA Sanitation and Water Project. This initiative included a comprehensive qualitative study to explore the effects of Menstrual Health Management (MHM) interventions in schools on the educational engagement of adolescent girls. The project involved the construction of sanitation facilities in over 260 schools throughout the Greater Accra Metropolitan Area. These facilities featured separate and secure toilets and changing rooms for girls, equipped with locks on doors, hygienic and safe disposal areas for used sanitary products, and handwashing facilities. Consequently, the rising awareness of menstrual health and government initiatives are key drivers behind the growth of the cyclic heavy menstrual bleeding market.

The growth of the heavy menstrual bleeding market is being impeded during the forecast period due to the increasing costs associated with research and development. The development of novel treatments, medications, and medical devices for managing heavy menstrual bleeding entails substantial investments in research and development. These expenses can pose a financial challenge for pharmaceutical and medical device companies, leading to a degree of hesitancy in the pursuit of innovative solutions. For example, as of September 2023, data from the House of Commons, a governmental institution based in the United Kingdom, revealed that the overall gross expenditure on research and development in the UK had risen to $80.91 billion in 2021, up from $75.17 billion in 2020. Hence, the mounting research and development costs represent a limiting factor in the growth of the heavy menstrual bleeding market.

The prominent companies in the cyclic heavy menstrual bleeding market are focused on the development of innovative medications like MYFEMBREE to gain a competitive edge in the industry. In a notable development, in May 2021, Myovant Sciences, a pharmaceutical company headquartered in the United States, in collaboration with Pfizer, another US-based pharmaceutical company, unveiled MYFEMBREE. This groundbreaking introduction received approval from the Food and Drug Administration (FDA), a US government agency. MYFEMBREE represents the first-ever once-daily treatment designed for the management of heavy menstrual bleeding linked to uterine fibroids in premenopausal women. Its treatment duration extends up to 24 months. Notably, this medication not only addresses heavy menstrual bleeding but also mitigates the risk of bone loss. It incorporates norethindrone acetate, a progestin, which is a crucial component when estrogen is prescribed to women with a uterus (womb). This innovative treatment marks a significant advancement in addressing heavy menstrual bleeding.

In October 2022, Unified Women's Healthcare, a healthcare company based in the United States specializing in women's healthcare treatment, completed the acquisition of Gennev for an undisclosed sum. This strategic move by Unified Women's Healthcare is aimed at enhancing its women's healthcare portfolio to offer improved healthcare outcomes and a superior patient experience across all stages of a woman's healthcare journey. Gennev, also based in the United States, is a company dedicated to providing feminine care services, offering a range of treatments that empower women to actively manage their health during and after menopause. This acquisition serves as a pivotal step in strengthening women's healthcare services.

Major players in the cyclic heavy menstrual bleeding market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Reckitt Benckiser Group Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

North America was the largest region in the cyclic menstrual bleeding market in 2023. The regions covered in cyclic heavy menstrual bleeding report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cyclic heavy menstrual bleeding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cyclic heavy menstrual bleeding market consists of revenues earned by entities by provide diagnostic testing, treatment planning and non-hormonal medications. The market value includes the value of related goods sold by the service provider or included within the service offering. The cyclic heavy menstrual bleeding market also includes sales of sanitary products, hormonal contraceptives, tranexamic acid and nonsteroidal anti-inflammatory drugs (NSAIDs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Cyclic Heavy Menstrual Bleeding Market Characteristics

3. Cyclic Heavy Menstrual Bleeding Market Trends And Strategies

4. Cyclic Heavy Menstrual Bleeding Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Cyclic Heavy Menstrual Bleeding Market Size and Growth

  • 5.1. Global Cyclic Heavy Menstrual Bleeding Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Cyclic Heavy Menstrual Bleeding Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Cyclic Heavy Menstrual Bleeding Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cyclic Heavy Menstrual Bleeding Market Segmentation

  • 6.1. Global Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Polymenorrhea
  • Oligomenorrhea
  • Metrorrhagia
  • 6.2. Global Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medication
  • Hormonal Therapy
  • Surgery
  • 6.3. Global Cyclic Heavy Menstrual Bleeding Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.4. Global Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users

7. Cyclic Heavy Menstrual Bleeding Market Regional And Country Analysis

  • 7.1. Global Cyclic Heavy Menstrual Bleeding Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Cyclic Heavy Menstrual Bleeding Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cyclic Heavy Menstrual Bleeding Market

  • 8.1. Asia-Pacific Cyclic Heavy Menstrual Bleeding Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cyclic Heavy Menstrual Bleeding Market

  • 9.1. China Cyclic Heavy Menstrual Bleeding Market Overview
  • 9.2. China Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cyclic Heavy Menstrual Bleeding Market

  • 10.1. India Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cyclic Heavy Menstrual Bleeding Market

  • 11.1. Japan Cyclic Heavy Menstrual Bleeding Market Overview
  • 11.2. Japan Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cyclic Heavy Menstrual Bleeding Market

  • 12.1. Australia Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cyclic Heavy Menstrual Bleeding Market

  • 13.1. Indonesia Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cyclic Heavy Menstrual Bleeding Market

  • 14.1. South Korea Cyclic Heavy Menstrual Bleeding Market Overview
  • 14.2. South Korea Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cyclic Heavy Menstrual Bleeding Market

  • 15.1. Western Europe Cyclic Heavy Menstrual Bleeding Market Overview
  • 15.2. Western Europe Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cyclic Heavy Menstrual Bleeding Market

  • 16.1. UK Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cyclic Heavy Menstrual Bleeding Market

  • 17.1. Germany Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cyclic Heavy Menstrual Bleeding Market

  • 18.1. France Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cyclic Heavy Menstrual Bleeding Market

  • 19.1. Italy Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cyclic Heavy Menstrual Bleeding Market

  • 20.1. Spain Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cyclic Heavy Menstrual Bleeding Market

  • 21.1. Eastern Europe Cyclic Heavy Menstrual Bleeding Market Overview
  • 21.2. Eastern Europe Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cyclic Heavy Menstrual Bleeding Market

  • 22.1. Russia Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cyclic Heavy Menstrual Bleeding Market

  • 23.1. North America Cyclic Heavy Menstrual Bleeding Market Overview
  • 23.2. North America Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cyclic Heavy Menstrual Bleeding Market

  • 24.1. USA Cyclic Heavy Menstrual Bleeding Market Overview
  • 24.2. USA Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cyclic Heavy Menstrual Bleeding Market

  • 25.1. Canada Cyclic Heavy Menstrual Bleeding Market Overview
  • 25.2. Canada Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cyclic Heavy Menstrual Bleeding Market

  • 26.1. South America Cyclic Heavy Menstrual Bleeding Market Overview
  • 26.2. South America Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cyclic Heavy Menstrual Bleeding Market

  • 27.1. Brazil Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cyclic Heavy Menstrual Bleeding Market

  • 28.1. Middle East Cyclic Heavy Menstrual Bleeding Market Overview
  • 28.2. Middle East Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cyclic Heavy Menstrual Bleeding Market

  • 29.1. Africa Cyclic Heavy Menstrual Bleeding Market Overview
  • 29.2. Africa Cyclic Heavy Menstrual Bleeding Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Cyclic Heavy Menstrual Bleeding Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Cyclic Heavy Menstrual Bleeding Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cyclic Heavy Menstrual Bleeding Market Competitive Landscape And Company Profiles

  • 30.1. Cyclic Heavy Menstrual Bleeding Market Competitive Landscape
  • 30.2. Cyclic Heavy Menstrual Bleeding Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck and Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Abbott Laboratories
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline Plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Cyclic Heavy Menstrual Bleeding Market Other Major And Innovative Companies

  • 31.1. Medtronic Plc
  • 31.2. Takeda Pharmaceutical Company Limited
  • 31.3. Eli Lilly and Company
  • 31.4. Amgen Inc.
  • 31.5. Boehringer Ingelheim International GmbH
  • 31.6. Reckitt Benckiser Group Plc
  • 31.7. Teva Pharmaceutical Industries Ltd.
  • 31.8. Mylan N.V.
  • 31.9. Bausch Health Companies Inc.
  • 31.10. Eisai Co. Ltd.
  • 31.11. Sun Pharmaceutical Industries Ltd.
  • 31.12. Perrigo Company PLC
  • 31.13. Dr. Reddy's Laboratories Ltd.
  • 31.14. Aurobindo Pharma Limited
  • 31.15. Cipla Limited

32. Global Cyclic Heavy Menstrual Bleeding Market Competitive Benchmarking

33. Global Cyclic Heavy Menstrual Bleeding Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cyclic Heavy Menstrual Bleeding Market

35. Cyclic Heavy Menstrual Bleeding Market Future Outlook and Potential Analysis

  • 35.1 Cyclic Heavy Menstrual Bleeding Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Cyclic Heavy Menstrual Bleeding Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Cyclic Heavy Menstrual Bleeding Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer